




11-21-02

1642.13

Patent Docket P1759R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Avi J. Ashkenazi et al. Serial No.: 09/589,395	Group Art Unit: 1642 Examiner: G. Nickol	RECEIVED NOV 22 2002 TECH CENTER 1600/2900
Filed: June 7, 2000 For: Apo-2L Receptor Agonist and CPT-11 Synergism	CERTIFICATE OF EXPRESS MAILING EXPRESS MAIL LABEL NO.: <u>EL889345554 US</u> <small>I hereby certify that this correspondence is being deposited with the United States Postal Service 'Express Mail Post Office to Addressee' service under 37 CFR 1.10 on the date indicated below and is addressed to 'Assistant Commissioner of Patents, Washington, D.C. 20231.</small> November 20, 2002  Diane L. Marschang	

RESPONSE TO COMMUNICATION


Assistant Commissioner of Patents
Washington, D.C. 20231

This paper is being filed in response to the Office Communication mailed November 7, 2002 setting forth a notice of non-compliant amendment pursuant to 37 CFR 1.121. Specifically, the Communication states that Applicants' response filed October 25, 2002 is not compliant because it does not include a marked-up version of the amended claims.

The undersigned submits that the response filed by Applicants on October 25, 2002 is compliant with all applicable rules since no changes or amendments were requested to the claims or to the specification. A copy of Applicants' Response is enclosed herewith. The undersigned apologizes for any confusion resulting from the inadvertent statement (i.e., typographical error) on page 1 of the Response concerning "entry of the following amendment" It is believed that the Response, in its entirety, clearly provides that no changes to any of the pending claims were intended or requested.

Respectfully submitted,

GENENTECH, INC

By: 


Diane L. Marschang
Reg. No. 35,600
Telephone No. (650) 225-5416

Date: November 20, 2002



09157

PATENT TRADEMARK OFFICE



Patent Docket P1759R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of	Group Art Unit: 1642
Avi J. Ashkenazi et al.	Examiner: G. Nickol
Serial No.: 09/589,395	
Filed: June 7, 2000	
For: Apo-2L Receptor Agonist and CPT-11 Synergism	

NOV 22 2002

TECH CENTER 1600/2900

RESPONSE

Box Non-fee Amendment
Assistant Commissioner of Patents
Washington, D.C. 20231

SIR:

This paper is being filed in response to the Office Action mailed April 25, 2002. Entry of the following Amendment and consideration of the remarks herein are respectfully requested.

1610
KD
12-18-02

In the claims:

6. (Twice Amended) A method of inducing apoptosis in mammalian cancer cells comprising exposing mammalian cancer cells to agonistic anti-DR5 receptor antibody and CPT-11 in an amount effective to synergistically induce apoptosis in said mammalian cancer cells.

7. (As filed) The method of claim 6 wherein said anti-DR5 receptor antibody is a monoclonal antibody.

8. (As filed) The method of claim 7 wherein said anti-DR5 receptor monoclonal antibody comprises a chimeric antibody.

9. (As filed) The method of claim 7 wherein said anti-DR5 receptor